Gastroesophageal Reflux Disease
📧 Sign up to get email alerts when something new happens for Gastroesophageal Reflux Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2012-12-20Clinical Trial Update: Tongue Exercises and Reflux Therapy for Upper Airway Resistance Syndrome [Phase 1]
A Phase 1 clinical trial evaluating tongue exercises and reflux therapy for upper airway resistance syndrome has been withdrawn.
-
FDA approval · 2012-12-19FDA Approved: FAMOTIDINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for famotidine from Teva Pharmaceuticals USA, Inc., signaling an approved modification to the produc…
-
FDA approval · 2012-12-17FDA Approved: FAMOTIDINE — Original Application (Lupin Pharmaceuticals,Inc.)
FDA approves Lupin Pharmaceuticals' famotidine as a generic product under an original ANDA, authorizing its marketing for approved indicatio…
-
FDA approval · 2012-12-12FDA Approved: FAMOTIDINE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for famotidine filed by Chartwell RX, LLC.
-
CLINICAL_TRIALS trial_result · 2012-12-11Clinical Trial Update: Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients [Phase 4]
Phase 4 trial evaluating symptom-adapted therapy with Nexium (esomeprazole) in gastroesophageal reflux disease; results have been posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-12-10Clinical Trial Update: A Study to Monitor Intragastric pH in Patients Taking Rabeprazole vs. Patients Taking Pantoprazole [Phase 1]
A Phase 1 study comparing intragastric pH in GERD patients treated with rabeprazole versus pantoprazole has completed.
-
CLINICAL_TRIALS trial_result · 2012-12-06Clinical Trial Update: The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis [Phase 2, Phase 3]
A Mayo Clinic–led clinical trial update describing Phase 2 and Phase 3 studies on the role of gastroesophageal reflux disease in eosinophili…
-
CLINICAL_TRIALS trial_result · 2012-12-03Clinical Trial Update: CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing [Phase 4]
Phase 4 study assessing whether CYP2C19 genetic polymorphism affects the accuracy of proton-pump inhibitor testing in gastroesophageal reflu…
-
CLINICAL_TRIALS trial_result · 2012-11-15Clinical Trial Update: A Randomized Controlled Trial of Laparoscopic Nissen Fundoplication Treatment of Patients With Chronic GERD [NA]
This document reports on a completed randomized controlled trial evaluating laparoscopic Nissen fundoplication for chronic gastroesophageal …
-
FDA approval · 2012-11-13FDA Approved: CIMETIDINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved Teva's supplemental application for cimetidine, resulting in an expanded label/approval for the drug.
-
FDA approval · 2012-11-13FDA Approved: CIMETIDINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva Pharmaceuticals USA, Inc.'s supplemental application for cimetidine, updating the product under an existing approval.
-
FDA approval · 2012-11-09FDA Approved: OMEPRAZOLE AND SODIUM BICARBONATE — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved Oceanside Pharmaceuticals' supplemental application for the fixed-dose combination of omeprazole and sodium bicarbonate, with u…
-
CLINICAL_TRIALS trial_result · 2012-11-09Clinical Trial Update: Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD) [Phase 2]
A Phase 2 study evaluating esophageal hypersensitivity in patients with gastroesophageal reflux disease (GERD) completed, with results poste…
-
FDA approval · 2012-11-02FDA Approved: OMEPRAZOLE — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for omeprazole submitted by Lannett Company, Inc. The approval pertains to a change to the marketed …
-
CLINICAL_TRIALS trial_result · 2012-10-31Clinical Trial Update: To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole [Phase 4]
This Phase 4 trial assesses whether once-daily esomeprazole 40 mg improves heartburn in patients who continued to have heartburn after rabep…
-
FDA approval · 2012-10-29FDA Approved: GOOD NEIGHBOR PHARMACY OMEPRAZOLE — Supplemental Application (Amerisource Bergen)
The FDA approved a supplemental application for Good Neighbor Pharmacy Omeprazole, submitted by Amerisource Bergen, for an additional use or…
-
CLINICAL_TRIALS trial_result · 2012-10-29Clinical Trial Update: Novel Imaging Techniques in Barrett's Esophagus [NA]
A completed clinical trial evaluating novel imaging techniques in Barrett's esophagus and gastroesophageal reflux disease.
-
CLINICAL_TRIALS withdrawal · 2012-10-26Clinical Trial Update: A Study to Evaluate the Role of Alternative Medicine in Difficult to Treat GERD Patients [NA]
A clinical trial evaluating the role of alternative medicine in difficult-to-treat gastroesophageal reflux disease has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2012-10-19Clinical Trial Update: A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions [Phase 1]
This Phase 1 study compares the relative bioavailability and pharmacodynamic profiles of Zegerid 20 mg capsule, Zegerid 20 mg powder for ora…
-
CLINICAL_TRIALS trial_result · 2012-10-11Clinical Trial Update: A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients [Phase 3]
A Phase 3 clinical trial assessing the safety and effectiveness of rabeprazole for treating gastroesophageal reflux disease in pediatric pat…
-
CLINICAL_TRIALS trial_result · 2012-10-11Clinical Trial Update: Optimal Dosing of Omeprazole in Neonates [Phase 2]
A Phase 2 trial evaluating the optimal dosing of omeprazole in neonates with gastroesophageal reflux disease has completed.
-
CLINICAL_TRIALS withdrawal · 2012-10-11Clinical Trial Update: Randomized Trial for Pharmacogenomics-based Proton Pump Inhibitor Therapy in Children [Phase 4]
A Phase 4 randomized trial evaluating pharmacogenomics-based proton pump inhibitor therapy in children for gastroesophageal reflux disease h…
-
CLINICAL_TRIALS trial_result · 2012-10-10Clinical Trial Update: A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) [Phase 4]
This Phase 4 study evaluated esomeprazole 40 mg once daily for GERD symptoms in patients who had prior full-dose proton pump inhibitor thera…
-
FDA approval · 2012-10-09FDA Approved: NEXIUM — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approved a supplemental application for Nexium (esomeprazole magnesium) submitted by AstraZeneca Pharmaceuticals LP.
-
FDA approval · 2012-10-09FDA Approved: PROTONIX DELAYED-RELEASE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
FDA approved a supplemental application for Protonix Delayed-Release (pantoprazole sodium) from Wyeth/Pfizer to modify/expand its labeling.